Genome Editing Market
Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR-Based Genome Editing, TALEN-Based Genome Editing, Zinc Finger Nucleases (ZFNs), and Other Technologies), by Application (Cell Line Engineering, Genetic Engineering (Plant and Animal), Gene Therapy, Drug Discovery and Development, and Other Applications), and by End Users (Biotechnology and Pharmaceutical Companies, Contract Research Organizations, Academic and Research Institutes, and Other End Users), Forecast Period (2026-2035)
Industry Overview
Genome editing market was valued at $13.2 billion in 2025 and is projected to reach $50.7 billion by 2035, growing at a CAGR of 14.5% during the forecast period (2026-2035). The market is growing due to the rapid advancement and adoption of CRISPR-based genome editing technologies, which offer higher precision, efficiency, and scalability compared to earlier methods, thereby accelerating their use across research and therapeutic applications. In parallel, the increasing focus on gene therapy for the treatment of genetic disorders and chronic diseases is driving demand for reliable genome editing platforms, as these technologies enable targeted modification at the molecular level. This trend is further supported by rising investments from biotechnology and pharmaceutical companies aimed at expanding gene-based pipelines and strengthening innovation capabilities. Additionally, the growing use of genome editing in drug discovery and cell line engineering is enhancing research productivity and reducing development timelines.
Market Dynamics
Rising Integration of Genome Editing in Drug Discovery and Preclinical Research
The increasing integration of genome editing technologies into drug discovery workflows is emerging as a key trend shaping the market. These tools enable precise gene modification, allowing researchers to develop more accurate disease models and identify novel therapeutic targets with higher confidence. As a result, pharmaceutical and biotechnology companies are leveraging genome editing to streamline preclinical validation and improve the efficiency of candidate screening. This approach reduces dependency on traditional trial-and-error methods and enhances the predictability of drug responses. Consequently, the growing reliance on genome editing for early-stage research is strengthening its role as a critical enabler in modern drug development pipelines.
Expansion of Genome Editing Applications in Agricultural Biotechnology
The expanding application of genome editing in agricultural biotechnology is contributing to the market’s steady growth. Advanced editing tools are being used to develop crop varieties with improved yield, disease resistance, and environmental adaptability, addressing global food security concerns. Unlike conventional genetic modification techniques, genome editing allows targeted alterations without introducing foreign DNA, which supports broader regulatory acceptance in several regions. This has encouraged increased investment from agritech companies and research institutions to accelerate crop improvement programs. As agricultural demand continues to evolve, the adoption of genome editing technologies is expected to expand further, reinforcing their importance beyond healthcare applications.
Market Segmentation
- Based on the technology, the market is segmented into CRISPR-based genome editing, TALEN-based genome editing, zinc finger nucleases (ZFNs), and other technologies.
- Based on the application, the market is segmented into cell line engineering, genetic engineering (plant and animal), gene therapy, drug discovery and development, and other applications.
- Based on the end users, the market is segmented into biotechnology and pharmaceutical companies, contract research organizations, academic and research institutes, and other end users.
CRISPR-Based Genome Editing Driving Technological Advancements
CRISPR-based genome editing remains the leading technology segment due to its high precision, efficiency, and adaptability across multiple applications. The ability to target specific genomic sequences with minimal off-target effects has accelerated its adoption in both research and therapeutic development. Increasing collaborations between biotechnology companies and academic institutions are expanding CRISPR applications in gene therapy and cell line engineering. Moreover, ongoing improvements in delivery methods and base-editing variants are enhancing its reliability and scalability. These factors position CRISPR as the primary driver of technological innovation within the genome editing market.
Gene Therapy Fueling Application Expansion
Gene therapy is a key application segment propelling market growth, as it offers potential cures for previously untreatable genetic disorders. The rising number of clinical trials using genome editing tools for inherited diseases and rare disorders underscores its growing relevance. Pharmaceutical and biotechnology firms are investing heavily in gene-editing platforms to develop precise, patient-specific therapies. Regulatory approvals for advanced gene therapies in major markets have further validated the commercial viability of this segment. Collectively, these developments make gene therapy a critical growth engine within the global genome editing market.
Regional Outlook
The global genome editing market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America: Leading Region in Genome Editing Market
North America dominates the global genome editing market, driven by substantial investments in biotechnology research, advanced infrastructure, and strong regulatory support for innovative therapies. The US, in particular, leads in clinical trials for CRISPR-based gene therapies and cell line engineering applications. Prominent industry participants, including Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, and Editas Medicine, have established robust R&D operations in the region. Additionally, collaborations between academic institutions and pharmaceutical companies are accelerating technology adoption. These factors collectively reinforce North America’s position as the largest contributor to market revenue.
Asia-Pacific: Fastest-Growing Region in Genome Editing Market
Asia-Pacific is the fastest-growing market, driven by increasing government funding for biotechnology initiatives, expanding research infrastructure, and rising adoption of genome editing in agriculture and therapeutics. Countries such as China, Japan, and India are actively supporting clinical trials and commercial applications, attracting both domestic and international players. Recent expansions by companies like GenScript Biotech Corporation and Takara Bio Inc. in the region are enhancing technology accessibility and scalability. The growing focus on precision medicine and crop improvement programs further propels market growth. Collectively, these trends position Asia-Pacific as a high-growth opportunity within the global genome editing market.
Market Players Outlook
The major companies operating in the global Genome Editing market include CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Merck KGaA, Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- CRISPR Therapeutics is progressing multiple in vivo gene editing programs using its proprietary LNP delivery platform. CTX310®, targeting ANGPTL3, is in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia, with updates expected in late 2026. The next-gen LPA program, CTX321™, shows doubled potency over CTX320™ in preclinical tests and is in IND/CTA-enabling studies, with updates also due in 2026. Preclinical candidates include CTX460™ for alpha-1 antitrypsin deficiency, entering clinical trials mid-2026, and CTX340™ for refractory hypertension, expected to start trials in early 2026.
- In July 2025, Synthego secured $100 million to advance its AI-driven gene editing technology. The funding will enhance its platforms for producing reagents and cells used in research and clinical trials. Gene editing involves identifying target genes, isolating reagents, performing edits, and verifying success, making the process complex and costly, as seen with expensive therapies like Novartis' Zolgensma for SMA.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global genome editing market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Genome Editing Market Sales Analysis – Technology | Application | End Users ($ Million)
- Genome Editing Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Genome Editing Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Genome Editing Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Genome Editing Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Genome Editing Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Genome Editing Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Genome Editing Market Revenue and Share by Manufacturers
- Genome Editing Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- CRISPR Therapeutics AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Editas Medicine, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Intellia Therapeutics, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck KGaA
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Thermo Fisher Scientific Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- CRISPR Therapeutics AG
- Key Company Analysis
- Global Genome Editing Market Sales Analysis by Technology ($ Million)
- CRISPR-Based Genome Editing
- TALEN-Based Genome Editing
- Zinc Finger Nucleases (ZFNs)
- Other Technologies
- Global Genome Editing Market Sales Analysis by Application ($ Million)
- Cell Line Engineering
- Genetic Engineering (Plant and Animal)
- Gene Therapy
- Drug Discovery and Development
- Others
- Global Genome Editing Market Sales Analysis by End Users ($ Million)
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
- Academic and Research Institutes
- Others
- Regional Analysis
- North American Genome Editing Market Sales Analysis – Technology | Application | End Users | Country ($ Million)
- United States
- Canada
- North American Genome Editing Market Sales Analysis – Technology | Application | End Users | Country ($ Million)
- European Genome Editing Market Sales Analysis – Technology | Application | End Users | Country ($ Million)
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Genome Editing Market Sales Analysis – Technology | Application | End Users | Country ($ Million)
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Genome Editing Market Sales Analysis – Technology | Application | End Users | Country ($ Million)
- Latin America
- Middle East and Africa
- Company Profiles
- Agilent Technologies, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Beam Therapeutics Inc.
- Bio-Rad Laboratories, Inc. Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- bluebird bio, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Caribou Biosciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cellectis S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CRISPR Therapeutics AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Danaher Corporation (Integrated DNA Technologies, Inc.)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Editas Medicine, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eurofins Scientific SE
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GenScript Biotech Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Horizon Discovery Group plc (PerkinElmer Inc.)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Intellia Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lonza Group Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA (MilliporeSigma)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- New England Biolabs, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- OriGene Technologies, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Precision BioSciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sangamo Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Synthego Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takara Bio Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Transposagen Biopharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Twist Bioscience Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Verve Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Agilent Technologies, Inc.
1. Global Genome Editing Market Research and Analysis by Technology, 2025–2035 ($ Million)
2. Global CRISPR-Based Genome Editing Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global TALEN-Based Genome Editing Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Zinc Finger Nucleases (ZFNs) Genome Editing Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Other Genome Editing Technologies Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Genome Editing Market Research and Analysis by Application, 2025–2035 ($ Million)
7. Global Genome Editing In Cell Line Engineering Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Genome Editing In Genetic Engineering Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Genome Editing In Gene Therapy Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Genome Editing In Drug Discovery and Development Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Genome Editing In Other Applications Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Genome Editing Market Research and Analysis by End Users, 2025–2035 ($ Million)
13. Global Genome Editing For Biotechnology and Pharmaceutical Companies Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Genome Editing For Contract Research Organizations Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Genome Editing For Academic and Research Institutes Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Genome Editing For Others End Users Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Genome Editing Market Research and Analysis by Region, 2025–2035 ($ Million)
18. North American Genome Editing Market Research and Analysis by Country, 2025–2035 ($ Million)
19. North American Genome Editing Market Research and Analysis by Technology, 2025–2035 ($ Million)
20. North American Genome Editing Market Research and Analysis by Application, 2025–2035 ($ Million)
21. North American Genome Editing Market Research and Analysis by End Users, 2025–2035 ($ Million)
22. European Genome Editing Market Research and Analysis by Country, 2025–2035 ($ Million)
23. European Genome Editing Market Research and Analysis by Technology, 2025–2035 ($ Million)
24. European Genome Editing Market Research and Analysis by Application, 2025–2035 ($ Million)
25. European Genome Editing Market Research and Analysis by End Users, 2025–2035 ($ Million)
26. Asia-Pacific Genome Editing Market Research and Analysis by Country, 2025–2035 ($ Million)
27. Asia-Pacific Genome Editing Market Research and Analysis by Technology, 2025–2035 ($ Million)
28. Asia-Pacific Genome Editing Market Research and Analysis by Application, 2025–2035 ($ Million)
29. Asia-Pacific Genome Editing Market Research and Analysis by End Users, 2025–2035 ($ Million)
30. Rest of the World Genome Editing Market Research and Analysis by Region, 2025–2035 ($ Million)
31. Rest of the World Genome Editing Market Research and Analysis by Technology, 2025–2035 ($ Million)
32. Rest of the World Genome Editing Market Research and Analysis by Application, 2025–2035 ($ Million)
33. Rest of the World Genome Editing Market Research and Analysis by End Users, 2025–2035 ($ Million)
1. Global Genome Editing Market Share by Technology, 2025 vs 2035 (%)
2. Global CRISPR-Based Genome Editing Market Share by Region, 2025 vs 2035 (%)
3. Global TALEN-Based Genome Editing Market Share by Region, 2025 vs 2035 (%)
4. Global Zinc Finger Nucleases (ZFNs) Genome Editing Market Share by Region, 2025 vs 2035 (%)
5. Global Other Genome Editing Technologies Market Share by Region, 2025 vs 2035 (%)
6. Global Genome Editing Market Share by Application, 2025 vs 2035 (%)
7. Global Genome Editing in Cell Line Engineering Market Share by Region, 2025 vs 2035 (%)
8. Global Genome Editing in Genetic Engineering Market Share by Region, 2025 vs 2035 (%)
9. Global Genome Editing in Gene Therapy Market Share by Region, 2025 vs 2035 (%)
10. Global Genome Editing in Drug Discovery and Development Market Share by Region, 2025 vs 2035 (%)
11. Global Genome Editing in Other Application Genome Editing Market Share by Region, 2025 vs 2035 (%)
12. Global Genome Editing Market Share by End Users, 2025 vs 2035 (%)
13. Global Genome Editing For Biotechnology and Pharmaceutical Companies Market Share by Region, 2025 vs 2035 (%)
14. Global Genome Editing For Contract Research Organizations Market Share by Region, 2025 vs 2035 (%)
15. Global Genome Editing For Academic and Research Institutes Market Share by Region, 2025 vs 2035 (%)
16. Global Genome Editing For Other End Users Market Share by Region, 2025 vs 2035 (%)
17. Global Genome Editing Market Research and Analysis by Region, 2025–2035 ($ Million)
18. US Genome Editing Market Size, 2025–2035 ($ Million)
19. Canada Genome Editing Market Size, 2025–2035 ($ Million)
20. UK Genome Editing Market Size, 2025–2035 ($ Million)
21. France Genome Editing Market Size, 2025–2035 ($ Million)
22. Germany Genome Editing Market Size, 2025–2035 ($ Million)
23. Italy Genome Editing Market Size, 2025–2035 ($ Million)
24. Spain Genome Editing Market Size, 2025–2035 ($ Million)
25. Russia Genome Editing Market Size, 2025–2035 ($ Million)
26. Rest of Europe Genome Editing Market Size, 2025–2035 ($ Million)
27. India Genome Editing Market Size, 2025–2035 ($ Million)
28. China Genome Editing Market Size, 2025–2035 ($ Million)
29. Japan Genome Editing Market Size, 2025–2035 ($ Million)
30. South Korea Genome Editing Market Size, 2025–2035 ($ Million)
31. Australia and New Zealand Genome Editing Market Size, 2025–2035 ($ Million)
32. ASEAN Economies Genome Editing Market Size, 2025–2035 ($ Million)
33. Rest of Asia-Pacific Genome Editing Market Size, 2025–2035 ($ Million)
34. Latin America Genome Editing Market Size, 2025–2035 ($ Million)
35. Middle East and Africa Genome Editing Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
